Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QL-1706-based induction therapy with omission of brachytherapy in locally advanced cervical cancer
ChiCTR2500106344Phase 2Not yet recruiting
- Sponsor
- Sun Yat-sen Memorial Hospital
- Start
- Jul 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of iparomlimab + tuvonralimab in Cervical Cancer (CC), sponsored by Sun Yat-sen Memorial Hospital. Primary endpoint: 2-year progression-free survival. Planned start Jul 2025; status: not yet recruiting.
02
Drugs
iparomlimab + tuvonralimab
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on ChiCTR2500106344.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500106344.